Recent advances in glycoconjugate-based therapeutics.

Area of Science:

• Glycobiology and Glycoconjugate Therapeutics
• Precision Medicine
• Synthetic Chemistry in Drug Development

Background:

• Glycoconjugates are crucial for molecular recognition but their heterogeneity historically limited therapeutic applications.
• Recent progress in synthetic and chemoenzymatic methods allows for the creation of structurally defined glycoconjugates.

Purpose of the Study:

• To review key advancements in glycoconjugate-based therapeutics developed over the last two years.
• To highlight the potential of precisely designed glycans in transforming glycobiology into a therapeutic platform.

Main Methods:

• Review of recent literature on synthetic chemistry, chemoenzymatic approaches, and glycoengineering.
• Analysis of emerging glycoconjugate therapeutic modalities, including vaccines, engineered proteins, and drug conjugates.

Main Results:

• Development of glycoconjugate vaccines.
• Glycoengineered peptides and proteins with enhanced pharmacological profiles.
• Glycosite-specific antibody-drug conjugates and glycan-mediated protein degradation.
• Glycolipid-engineered lipid nanoparticles for nucleic acid delivery.

Conclusions:

• Precise glycan design is enabling novel therapeutic strategies.
• Glycoconjugate-based medicines represent a rapidly advancing frontier in precision medicine.
• Integration of synthetic, analytical, and computational approaches will drive future drug development.